bryan johnson ghk cu How one entrepreneur is tackling humanity's most pressing problems TUCC | Bryan-Johnson - TUCC

Analyst projections place possible approval in late 2027 or 2028, but those are estimates, not confirmed dates

Med Clin Exp 2004;27:10-3

Behavior therapy and nootropic medications are the mainstays of ADHD treatment

What the research firmly supports: BPC-157's gut healing, vascular, and neuroprotective mechanisms (strong preclinical evidence) Thymosin Alpha-1's immune modulating and T-cell restorative effects (strong preclinical + clinical evidence in viral disease) TB-500's cardiovascular repair and angiogenic properties (strong preclinical, early human data) What the research does not yet confirm: Randomised controlled trial data specifically in long COVID populations Optimal dosing, sequencing, and duration specifically for PASC Long-term safety data for extended post-viral use This doesn't mean these peptides don't work for long COVID

It is designed for controlled laboratory investigations involving copper peptide signaling, extracellular matrix pathway research, collagen-associated biology, dermal response models, tissue-remodeling pathways, oxidative stress biology, cellular repair-associated signaling, and peptide-metal complex research

Bpc-157